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SUMMARY. Viral hepatitis is responsible for great health,
social and economic burden both globally and in the UK.
This study aimed to assess the research funding awarded to
UK institutions for viral hepatitis research and the relation-
ship of funded research to clinical and public health burden
of viral hepatitis. Databases and websites were systemati-
cally searched for information on infectious disease research
studies funded for the period 1997–2010. Studies specifi-
cally related to viral hepatitis research were identified and
categorized in terms of funding by pathogen, disease and by
a research and development value chain describing the type
of science. The overall data set included 6165 studies (total
investment £2.6 billion) of which £76.9 million (3.0%) was
directed towards viral hepatitis across 323 studies (5.2%).
By pathogen, there were four studies specifically investigat-
ing hepatitis A (£3.8 million), 69 studies for hepatitis B
(21.4%) with total investment of £14.7 million (19.1%) and
236 (73.1%) hepatitis C studies (£62.7 million, 81.5%).
There were 4 studies investigating hepatitis G, and none
specifying hepatitis D or E. By associated area, viral hepatitis
and therapeutics research received £17.0 million, vaccinolo-
gy £3.1 million and diagnostics £2.9 million. Preclinical
research received £50.3 million (65.4%) across 173 studies,
whilst implementation and operational research received
£19.4 million (25.3%) across 128 studies. The UK is
engaged in much hepatology research, but there are areas
where the burden is great and may require greater focus,
such as hepatitis E, development of a vaccine for hepatitis C,
and further research into hepatitis-associated cancers. Pri-
vate sector data, and funding information from other coun-
tries, would also be useful in priority setting.
Keywords: hepatitis A, hepatitis B, hepatitis C, funding,
research.
INTRODUCTION
A range of factors makes preventing and managing hepati-
tis infections across the different viruses, a challenging and
complex task, and these include susceptibility of different
populations, the availability of vaccines, the length of the
latent period, severity of symptoms and secondary out-
comes such as carcinomas and the multiple modes of
transmission. These factors are highlighted in prevalence
and mortality data across different world regions and
countries. Prevalence of hepatitis A is highest in sub-Saha-
ran Africa and parts of south-east Asia, where infection is
often at a young age (and asymptomatic), with the lowest
prevalence found in some high-income countries where
few individuals become infected in childhood [1].
Mortality of hepatitis A, B and C in the United States is
most common in the 45–64 age group, with much higher
mortality rates in males compared with females, and signif-
icant differences by ethnic group; there were a total of
18 473 viral hepatitis-related deaths in 2010, with
17 113 of these related to hepatitis C [2]. Approximately
14 million people in Europe are estimated to be infected
with hepatitis B and 9 million with hepatitis C, causing
36 000 and 86 000 deaths, respectively [3]. Worldwide,
hepatitis B causes 1 million deaths annually with the
majority of these in sub-Saharan Africa [4]. The 2005 glo-
bal burden of hepatitis E was estimated to include 20.1
million incident infections with 3.4 million symptomatic
cases, 70 000 deaths and 3000 stillbirths [5]. Within the
UK, prevalence of hepatitis A is considered to be very low
compared with global data [1], as is hepatitis B prevalence
Abbreviations: DALY, disability-adjusted life years; HBV, hepatitis
B virus; HCAI, Healthcare-associated infections; HCV, hepatitis C
virus; IQR, interquartile range; MRC, Medical Research Council.
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[6]. Hepatitis C prevalence is estimated at 1.38% in men
and 0.42% in women, with mean number of 7571 new
infections per year between 1986 and 2000 [7].
UK research institutions received at least £2.6 billion of
public and philanthropic funding to carry out infectious
disease research between 1997 and 2010 from a variety of
national and international funding sources [8]. These
included the Wellcome Trust, Medical Research Council,
Department of Health, Bill & Melinda Gates Foundation,
European Commission, and a range of other bodies and
departments and research charities. This funding was spent
on all types of science along the research pipeline, from
laboratory studies to operational research and translational
medicine. We report here, the research funding that was
awarded to UK institutions specifically for viral hepatitis-
associated infection research, along with temporal trends
and the relative proportions allocated. We assess how clo-
sely the topics funded relate to the clinical and public
health burden of viral hepatitis, seeking to identify poten-
tial funding gaps that policy makers and funders can be
encouraged to focus on in future, and areas where the UK
has clear research strengths.
METHODS
The analyses in this paper focussed on studies funded in a
14-year period (1997–2010 inclusive) that were clearly
relevant to, or had specific mention of, viral hepatitis dis-
ease. Several studies specifically referred to more than one
type of viral hepatitis (e.g. hepatitis B and C); these were
counted in all relevant categories. No private sector fund-
ing was included in this analysis as the publicly available
data are very limited from these sources and were consid-
ered to be under-representative.
The methods have been described in detail elsewhere [8]
and are reiterated here. The overarching data set was
obtained from the major sources of public and charitable
funding for infectious disease research studies, including
the Wellcome Trust, Medical Research Council and other
research councils, UK government departments, European
Commission, Bill and Melinda Gates Foundation and other
research charities (Fig. 1). Data collection was performed
by (i) downloading all data from the funder website and
manually filtering the infectious disease studies; or (ii)
searching open access databases on the funder website for
infection-related keyword terms or (iii) contacting the fun-
der directly and requesting details of their infection studies.
Funders were identified through author’s knowledge of the
research and development (R&D) landscape, searches of the
internet, the Infectious Disease Research Network and data-
bases such as the National Research Register, Clinicaltri-
als.gov and the Association for Medical Research Charities.
Author MGH performed the majority of data extraction,
with support from author JRF. Each study was assigned to
as many primary disease categories as appropriate [9].
Within each category, topic-specific subsections (including
specific pathogen or disease) were documented. Studies
were also allocated to one of four R&D categories: preclini-
cal; phase 1, 2, or 3; product development and implementa-
tion and operational research (including surveillance,
epidemiology and statistical and modelling projects).
Funders were either considered in their own right, or for
convenience, some were grouped into categories, such as
in-house university funding, research charities, and govern-
ment departments. A total of 26 funder categories were
used [9]. Studies were excluded if (i) they were not immedi-
ately relevant to infection; (ii) they were veterinary infec-
tious disease research studies; (iii) they concerned the use
of viral vectors to investigate noncommunicable diseases;
(iv) they were grants for symposia or meetings or (v) they
included UK researchers, but with the funding awarded to
and administered through a non-UK institution. Studies
were categorized as viral hepatitis research where there
was specific mention or a clear implication of relevance to
viral hepatitis in the project title or abstract. Unfunded
studies were excluded. Grants awarded in a currency other
than pounds sterling were converted to UK pounds using
the mean exchange rate in the year of the award. All
awards were adjusted for inflation and reported in 2010
UK pounds. Analysis was carried out in Microsoft Excel and
Access (versions 2000 and 2007) and Stata (version 11)
(StataCorp, College Station, Texas, USA). Further informa-
tion on methods and lists of categories are available online
(http://www.researchinvestments.org/data). Data were
compared with disease burden using disability-adjusted life
years (DALYs), sourced from the Global Burden of Disease
study carried out by the Institute for Health Metrics and
Evaluation (Washington, Seattle) [10].
RESULTS
We identified 6165 studies funded within the 14-year
study period and covering all infectious disease research,
representing a total investment of £2.6 billion. There were
323 studies of relevance to viral hepatitis research, com-
prising 5.2% of total infectious disease research projects.
These were awarded £76.9 million, 3.0% of the total
spend, with a median award of £114 943 (interquartile
range £40 075–246 841) and mean award of £238 161
(standard deviation £404 983) (Table 1). Mean total
annual investment was £5.5 million. The ten studies
awarded the greatest funding are shown in Appendix S1.
Of the 323 viral hepatitis projects (Table 1), there were
four studies (1.2% of all hepatology projects) specifically
investigating hepatitis A, with total investment of £3.8 mil-
lion (5.0% of total hepatology investment). Hepatitis B was a
focus in 69 studies (21.4%) with total investment of £14.7
million (19.1%). There were 236 (73.1%) hepatitis C stud-
ies, receiving investment of £62.7 million (81.5%). A com-
parison of funding for these pathogens against selected other
© 2014 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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infectious diseases is shown in Appendix S2. There were four
studies investigating hepatitis G, and none specifying hepati-
tis D or E. Not all studies specified a pathogen; some merely
referred to viral hepatitis as an area of focus (e.g. one study
title was ‘Determining the prevalence of chronic viral hepati-
tis in Tower Hamlets Bengali population’).
By cross-cutting theme across viral hepatitis studies
(Table 1), there were 35 studies (10.8%) investigating hep-
atitis and therapeutics, with total investment of £17.0
million (22.1%). There were 14 studies (4.3%) focusing on
vaccinology, receiving investment of £3.1 million (4.1%).
Diagnostics was a focus of 31 studies (9.6%), with invest-
ment of £2.9 million (3.8%). Research incorporating
associated cancers received funding of £0.5 million across
five studies, and intravenous drug use was studied in 36
projects (funding received £4.5 million). Viral hepatitis
with a global health focus was evident from 13 studies
(4.0%), with investment of £4.3 million (5.5%); this differs
greatly from the entire infectious disease data set
where global health studies account for 35.6% of the
funding [8].
Along the R&D value chain (Table 2), preclinical research
received £50.3 million (65.4%) across 173 studies (53.6%),
phase I to III studies received just £0.5 million (0.7%) from
3 studies (0.9%), product development research received
£6.7 million (8.7%) across 19 studies (5.9%) and implemen-
tation and operational research received £19.4 million
(25.3%) across 128 studies (39.6%). There were no clear
temporal trends in the levels of overall funding (Fig. 2a),
and specifically there was reduced funding for hepatitis B
and C from 1997–2004 to 2005–2010 (Table 3). This
decrease was also reflected in the relative investment in rela-
tion to DALYs from 2004 and 2010 (Table 3). The propor-
tion of funding for preclinical research appears to have
325 922 studies screened
- 170 452 NaƟonal Research Register     
- 25 113 European Commission
- 7 513 Bill & Melinda Gates FoundaƟon
- 14 660 Wellcome Trust
- 1 074 Health Technology Assessment
- 6 346 ESRC
- 30 Health InfecƟon Society 
- 1 583 BriƟsh Heart FoundaƟon 
- 266 AcƟon Medical Research 
- 27 NaƟonal InsƟtute for Health Research 
- 24 BriƟsh HIV AssociaƟon 
- 150 BriƟsh Lung FoundaƟon 
- 65 BriƟsh Society for AnƟmicrobial Chemotherapy 
- 98 619 NaƟonal InsƟtute for Health
4 240 studies provided to authors by :
- 2 016 Medical Research Council 
- 321 BBRSC 
- 55 MeningiƟs UK 
- 272 MeningiƟs Research FoundaƟon 
- 747 AssociaƟon of Medical Research ChariƟes 
- 52 Department for InternaƟonal Development 
- 547 Cancer Research UK 
- 60 Chief ScienƟst’s Oﬃce, Scotland 
- 41 Health ProtecƟon Agency
- 34 Northern Ireland R&D oﬃce
- 95 directly from researchers
314 867 studies excluded:
- not infecƟon-related
- veterinary studies
- non-UK host recipient
-
9745 studies eligible 
for detailed review
3580 studies excluded from analysis:
- unfunded studies
- Industry funded
6165 studies eligible for analysis
323 related to viral hepaƟƟs
Fig. 1 Flowchart of study methodology.
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broadly increased in recent years (Fig. 2b). The Medical
Research Council provided the greatest quantities of invest-
ment in viral hepatitis research (£27.7 million, 35.9%).
DISCUSSION
This study is the first systematic analysis of research funding
for viral hepatitis. Over the 14-year study period analysed,
323 studies were identified that related to viral hepatitis
where public or charitable funding had been awarded to a
UK institution. The most studied pathogen was hepatitis C
(236 studies, £62.7 million). Preclinical science received
greatest investment along the R&D value chain, followed by
implementation research, and very little for phase I–III trials
and product development studies. The large difference
between mean and median award (and wide interquartile
ranges and associated standard deviation) demonstrates
there were a large number of relatively small grants, set
alongside a few large investments. The Medical Research
Council invested the greatest amount of funding.
Using the 2004 burden data (which is the temporal
mid-point of this study), the investment in hepatitis C
research compared with DALYs is actually relatively high
(£65.67), as compared with hepatitis B (£7.12) and also
other disease areas within the data set (for example, tuber-
culosis with investment of £4.54 per DALY) [11] so per-
haps the UK has strengths in viral hepatitis research
(particularly preclinical studies). However, any current
measure of burden will only take into account currently
diagnosed cases, and not adequately convey the likely
greatly increased future burden of hepatitis C in particular.
The current levels of investment are likely not an over-
investment. It also appears that investment in both hepati-
tis B and C are declining over this time period, and the rel-
ative investment in these pathogens against the burden of
disease has dropped – a worrying situation if this is an
actual trend. The global acute burden of hepatitis E is
likely to be similar to that each of hepatitis A and B [12]
so the clear lack of any notable investment in this data set
is surprising and arguably should be addressed.
There are demonstrably different ways to present the
hepatology-related data from the Global Burden of Disease
study, and caution is appropriately advised when interpret-
ing the study findings; viral hepatitis burden can be pre-
sented by just the acute infection, or including the chronic
burdens of cirrhosis and cancers [12]. There are also other
measures of burden that could be used to assess research
investments, such as mortality, incidence, prevalence or
economic burden. It would be useful also to quantify
investments into viral hepatitis awarded since 2010. The
limitations of this study are described fully elsewhere [8]
and reiterated here. There was little publicly available data
from the pharmaceutical industry. Hence, there is a data
gap in relation to funding of clinical trials and development
of vaccines and diagnostics, which the pharmaceutical andT
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biotechnology industry are financing. Beyond disease
burden, other measures, such as economic burden should
also be utilized when prioritizing limited resources, but lit-
tle information is available regarding the economic impact
of viral hepatitis infections. We rely on the original data
being complete and accurate and were unable to take into
account distribution of funds from the lead institution to
collaborating partners, nor could we realistically assess
quantity of each award given to overheads, the impact of
the introduction of full-economic costing, or distribution of
funding along each year of the award (for simplicity, all
funding was assumed to have been awarded at the start of
the grant). Also, assigning studies to categories is a subjec-
tive process – although we used at least two researchers to
do this to reduce interobserver error. Our study focuses on
UK-led investments – we do not know if similar patterns
(e.g. a dominance of preclinical research and lack of public
or charitably funded clinical trials) would also emerge if
the analysis was repeated for other high-income countries.
We have not here measured either the outputs or impact
of funded research.
The UK is well-placed to contribute to many of the priority
research areas that need additional funding, given particular
focuses on preclinical science as well as operational and
implementation research. However, there is a need for fund-
ers in other countries to provide similar and detailed infor-
mation on funded studies, and so build a global research
funding database – the World Health Organisation are
encouraging efforts in this area in creating a global R&D
observatory [13]. This could be used for analytical work to
identify gaps in research funding, reduce unnecessary dupli-
cation of research investments, prioritize health and social
policy decisions and help inform resource allocation for glo-
bal research priorities. Recent years have seen huge progress
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in the treatment of HBV and HCV. With effective vaccina-
tion, diagnostics and treatment, there are still important
questions about how to eradicate human reservoirs of HBV
infection requiring preclinical research. However, develop-
ments of highly active, well tolerated and curative HCV
treatments demand more investment in strategic clinical
research to understand best how these drugs may abate the
HCV epidemic. Preclinical R&D for HCV vaccination remains
an important area of potential development but progress has
been slow to date and the prospects of effective vaccination
remain distant. Given the global burden of hepatitis E, there
may be some valid research questions surrounding the distri-
bution and uptake of a vaccine within the regions of highest
burden.
ACKNOWLEDGEMENTS
We thank the Infectious Disease Research Network for
their contribution to this work, and acknowledge the assis-
tance of the research and development funding agencies
for provision of data.
FUNDING
This study was carried out alongside routine duties.
CONTRIBUTORS
MGH designed the study and collated the data set. JRF
checked and refined the data set. MGH and JRF undertook
data analysis and created the graphs and figures with
input from GSC, GF and RA. MGH interpreted the data and
wrote the draft and final versions. GSC, GF, JRF and RA
commented on the data set, draft paper and final version.
All authors reviewed and approved the final version. MGH
is guarantor of the paper.
CONFLICT OF INTEREST STATEMENT
MGH works for the Infectious Disease Research Network,
which has supported this work and is funded by the UK
Department of Health. JRF has received funds from the
Wellcome Trust and is a steering group member for the
Infectious Disease Research Network. RA has received
research funding from the Medical Research Council, the
National Institute for Health Research and the UK Depart-
ment for International Development. RA is a member of
the Medical Research Council Global Health Group. GF has
received funding from companies that market products for
the treatment of viral hepatitis including BI, BMS, GSK,
Merck, Roche, Janssen, Novartis and Gilead.
REFERENCES
1 Jacobsen KH, Wiersma ST. Hepatitis
A virus seroprevalence by age and
world region, 1990 and 2005. Vac-
cine 2010; 28(41): 6653–6657.
2 Ly KN, Xing J, Klevens RM et al.
Causes of death and characteristics
of decedents with viral hepatitis,
United States, 2010. Clin Infect Dis
2014; 58(1): 40–49.
3 Van de Laar MJW, Lopalco PL.
World Hepatitis Day: a timely remin-
der of the challenges ahead. Euro
Surveill 2008; 13(21): pii: 18883.
4 Lavanchy D. Hepatitis B virus epide-
miology, disease burden, treatment,
and current and emerging preven-
tion and control measures. J Viral
Hepat 2004; 11(2): 97–107.
5 Rein DB, Stevens GA, Theaker J et al.
The global burden of hepatitis E virus
genotypes 1 and 2 in 2005. Hepatolo-
gy 2012; 55(4): 988–997.
6 European Centre for Disease
Prevention and Control. Hepatitis B
and C in the EU Neighbour-
hood: Prevalence, Burden of Dis-
ease and Screening Policies.
Stockholm: European Centre for
Disease Prevention and Control,
2010.
7 Balogun MA, Vyse AJ, Hesketh LM
et al. Estimating hepatitis C infection
acquired in England, 1986–2000.
Epidemiol Infect 2009; 137(9):
1249–1254.
8 Head MG, Fitchett JR, Cooke MK
et al. UK investments in global infec-
tious disease research 1997–2010:
a case study. Lancet Infect Dis 2013;
13(1): 55–64.
9 ResIn - Research Investments in
Global Health. Available at: http://
www.researchinvestments.org (acce-
ssed 4 July 2014).
10 World Health Organisation. The
Global Burden of Disease: 2004
update. Geneva, Switzerland: World
Health Organization, 2008.
11 Head MG, Fitchett JR, Cooke MK
et al. Investments in respiratory
infectious disease research 1997–
2010: a systematic analysis of UK
funding. BMJ Open 2014; 4(3):
e004600.
12 Cooke GS, Lemoine M, Thursz M
et al. Viral hepatitis and the Global
Burden of Disease: a need to
regroup. J Viral Hepat 2013; 20(9):
600–601.
13 Røttingen J-A, Regmi S, Eide M
et al. Mapping of available health
research and development data:
what’s there, what’s missing, and
what role is there for a global
observatory? Lancet 2013; 382
(9900): 1286–307.
SUPPORTING INFORMATION
Additional Supporting Information
may be found in the online version of
this article:
Appendix S1: The ten viral
hepatitis studies awarded the greatest
funding.
Appendix S2: Comparison of
funding for hepatitis A, B and C with
other selected infectious diseases.
© 2014 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
Funding in viral hepatitis research 237
